Although PD-L1 expression is not the optimal biomarker, it is to date the only relevant one in certain types of cancer, and it is clearly associated with better outcomes in non-small cell lung cancer (NSCLC), gastric and cervical cancer treated with PD-1, or bladder and triple negative breast cancer treated with PD-L1 [94]. This evidence concerns the gene CD274 and cancer.